TRACK-BD: Brain-derived tau for monitoring brain injury and treatment response after acute ischemic stroke
Acute ischemic stroke causes rapidly evolving brain injury, yet current imaging provides only intermittent snapshots and cannot readily monitor ongoing tissue damage or biological treatment effects. TRACK-BD aims to establish plasma brain-derived tau (BD-tau) as a blood-based marker for monitoring injury progression and treatment response. Building on evidence that BD-tau tracks infarct growth and responds to treatment, the scientists will analyze hourly blood samples collected over 48 hours from 100 stroke patients to identify a robust, clinically interpretable measure of change. They will then validate this measure against serial magnetic resonance imaging in the international ESCAPE-CORE cohort, examining infarct growth, edema, hemorrhagic transformation and microvascular dysfunction. Finally, the scientists will develop and benchmark an ultrasensitive, rapid point-of-care assay for repeated BD-tau measurement. TRACK-BD seeks to lay the foundation for real-time molecular monitoring of stroke and more efficient evaluation of new therapies.